Medicenna Therapeutics Corp. (TSX: MDNA)

Medicenna Therapeutics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Selling, General & Admin	7.87	7.87	7	7.76	6.53	2.38
Research & Development	10.8	10.8	9.3	14.72	10.87	5.87
Operating Expenses	18.67	18.67	16.3	22.47	17.4	8.25
Operating Income	-18.67	-18.67	-16.3	-22.47	-17.4	-8.25
Interest & Investment Income	1.2	1.2	0.91	0.07	0.31	0.01
Net Interest Expenses	1.2	1.2	0.91	0.07	0.31	0.01
Currency Exchange Gain (Loss)	-0.07	-0.07	1.65	-0.17	-0.21	-0.04
Other Non Operating Income (Expenses)	-7.92	-7.92	3.7	-	-	-
EBT Excluding Unusual Items	-25.47	-25.47	-10.05	-22.58	-17.29	-8.28
Pretax Income	-25.47	-25.47	-10.05	-22.58	-17.29	-8.28
Net Income	-25.47	-25.47	-10.05	-22.58	-17.29	-8.28
Net Income to Common	-25.47	-25.47	-10.05	-22.58	-17.29	-8.28
Shares Outstanding (Basic)	70	70	65	54	50	32
Shares Outstanding (Diluted)	70	70	65	54	50	32
Shares Change (YoY)	7.57%	7.57%	19.25%	9.31%	55.68%	24.25%
EPS (Basic)	-0.37	-0.37	-0.16	-0.42	-0.35	-0.26
EPS (Diluted)	-0.37	-0.37	-0.16	-0.42	-0.35	-0.26
Free Cash Flow	-16.26	-16.26	-12.66	-23.58	-15.31	-5.42
Free Cash Flow Per Share	-0.23	-0.23	-0.20	-0.43	-0.31	-0.17
EBITDA	-18.67	-18.67	-16.3	-22.44	-17.36	-8.24
D&A For EBITDA	0	0	0	0.04	0.04	0.01
EBIT	-18.67	-18.67	-16.3	-22.47	-17.4	-8.25

Source: S&P Capital IQ. Standard template.